Progress on the Canadian HIV Vaccine Initiative

Supporting HIV prevention is essential while continuing to progress towards the goal of developing a safe and effective HIV.  Since its inception, the CHVI has made important progress on a number of fronts. Some of the key successes of the CHVI include:

• Providing $16 million in funding to Canada-Africa research teams to build clinical trial capacity for HIV prevention trials;
• providing over $3 million in funding for projects to strengthen capacity and promote greater involvement and collaboration among researchers in Canada and developing countries;
• providing $2 million to the World Health Organization to strengthen regulatory capacity in developing countries;
• supporting Canadian researchers to focus on new ideas and novel approaches towards the development of a safe and effective vaccine;
• providing more than $500,000 in funding to strengthen Canada’s contribution to HIV vaccine-related policy development and community engagement efforts;
• conducting research on key policy issues, and identifying opportunities for new HIV prevention technologies and private-public sector partnerships; and
• providing more than $750,000 to the Global HIV Vaccine Enterprise to foster collaboration among their stakeholders; identifying the latest scientific developments and gaps in HIV vaccine  research; and further developing their global Scientific Strategic Plan.

There are many steps on the road to an HIV vaccine from basic lab research, to developing a candidate vaccine, to testing it in regulated clinical trials, to finally getting it approved for use.